



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-S protein [P17] Ab03449-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: P17

Alternative Name(s) of Target: Spike glycoprotein; Receptor Binding Domain; SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; S glycoprotein; E2; Peplomer protein

UniProt Accession Number of Target Protein: P0DTC2

Published Application(s): in vivo, neutralizing, SPR, ELISA, IF

Published Species Reactivity: SARS-CoV-2

Immunogen: The original antibody was generated in the screening studies by using recombinant RBD of SARS-CoV-2 as a target against a fully human naive antibody library.

Specificity: The antibody binds the Spike protein of the SARS-CoV-2. The antibody does not crossreact with SARS-CoV RBD.

Application Notes: The specificity of the antibody was confirmed by ELISA analysis (EC50 = 29 pM). Surface plasmon resonance (SPR) assays demonstrated that the antibody bound to SARS-CoV-2 RBD with a high affinity of 96 pM. Immunofluorescence staining showed that the antibody prevented SARS-CoV-2 infection in a dosedependent manner in Vero cells. Pseudovirus neutralization assay (PSV) in Huh7 cells and standard 50% plaque reduction neutralization tests (PRNT) in Vero cells, both showed that the antibody exhibited stronger neutralizing activity with IC50 and PRNT50 values of 165 and 195 pM, respectively. The antibody conferred effective protection in animal models. The structure of the Fab fragment and a prefusion stabilized SARSCoV-2 S ectodomain trimer was characterized using single-particle cryo-EM. The antibody was employed together with H014 to develop a therapeutic antibody cocktail against SARS-CoV-2 with neutralizing properties (Yao et al., 2021; PMID: 33262452).

Antibody First Published in: Yao et al. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. Cell Res. 2021 Jan;31(1):25-36. [PMID:33262452](#)

Note on publication: The original paper describes the development of a human antibody cocktail.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.